Glaxo won't renew PDI sales contract

Share this article:
GlaxoSmithKline said it would not renew its 2007 sales engagement with contract sales firm PDI.
PDI said the Glaxo deal represents $65 million to $70 million in annual revenue and will expire as scheduled on Dec. 31. PDI's revenue for 2005 was $319 million.

“While we are disappointed with this decision, we are proud of the work we have done for GSK over the past three years and look forward to working with them again in the future,” PDI CEO Michael Marquardt said in a statement. “Our immediate priority is to develop other opportunities to redeploy our employees who comprise this sales team.”

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?